Another Novo Nordisk profit warning ‘still possible,’ says BofA

After Novo Nordisk (NVO) announced an EBIT guide cut on restructuring costs, with the EBIT growth guidance range lowered from 10%-16% to 4%-10%, BofA noted that this was the company’s third profit warning and argues that another one is “still possible” given the current “disappointing” total prescriptions trajectory. BofA has a Neutral rating and price target of DKK 375 on Novo Nordisk shares.